Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Novogene CoSHSE:688315 -2.93%84 Interest Coverage is 76.70 as of Mar. 2026, which is 16% below its 10-year median of 90.95. GuruFocus rates SHSE:688315 with a GF Score™ of 84/100 and a GF Value™ of ¥15.99 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 376 Biotechnology companies, Novogene Co ranks worse than 50.8% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Novogene Co's
Operating Income
for the
three
months ended in Mar. 2026 was ¥44 Mil. Novogene Co's Interest Expense for the
three
months ended in Mar. 2026 was ¥-1 Mil.
Novogene Co's interest coverage for the quarter that ended in Mar. 2026 was 76.70.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Novogene Co Ltd has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Novogene Co's Interest Coverage or its related term are showing as below:
SHSE:688315'
s Interest Coverage Range Over the Past 10 Years
Min: 6.25 Med: 90.95 Max: 203.42
Current: 99.7
SHSE:688315's Interest Coverage is ranked worse than 50.8% of 376
companies
in the Biotechnology industry
Industry Median: 106.135
vs SHSE:688315: 99.70
Novogene Co (SHSE:688315) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Novogene Co Interest Coverage Related Terms
Novogene Co Interest Coverage Historical Data
* Premium members only.
The historical data trend for Novogene Co's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
SHSE:688315 vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, Novogene Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novogene Co Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Novogene Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Novogene Co's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novogene Co (SHSE:688315) has a Interest Coverage of 76.70 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Novogene Co and its competitors. This is 16% below median its historical median of 90.95. Over the past decade, Novogene Co's Interest Coverage has ranged from 6.25 to 203.42. According to the industry distribution chart, Novogene Co ranks #191 out of 376 companies in the Biotechnology industry, placing it in the top 50.8%.
Is Novogene Co's Interest Coverage too high?
Novogene Co's current Interest Coverage of 76.70 is 16% below median its 10-year median of 90.95. Over the past 10 years, this metric has ranged from a low of 6.25 to a high of 203.42. The Biotechnology industry median Interest Coverage is 106.14. Novogene Co's value of 76.70 is 27.7% below this industry median. Based on the distribution chart, Novogene Co ranks #191 out of 376 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Novogene Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novogene Co's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Novogene Co ranks #191 out of 376 companies for Interest Coverage. This places Novogene Co in the lower half of its industry. The industry median Interest Coverage is 106.14. Novogene Co's value of 76.70 is 27.7% below this benchmark. Historically, Novogene Co's own Interest Coverage has ranged from 6.25 to 203.42 over the past decade. While the company's 10-year median is 90.95 vs. the industry median of 106.14, Novogene Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.14, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novogene Co's current Interest Coverage of 76.70 is 27.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Novogene Co and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novogene Co's current Interest Coverage is 76.70, which is 16% below median its own 10-year median of 90.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novogene Co stock overvalued right now?
Based on GuruFocus' analysis, Novogene Co (SHSE:688315) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥15.99, compared to a current price of ¥11.94 — trading 25.3% below its estimated fair value. The current Interest Coverage is 76.70, which is 16% below median its 10-year median of 90.95 and 27.7% below the Biotechnology industry median of 106.14. Novogene Co's overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Novogene Co (SHSE:688315), the current Interest Coverage is 76.70 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novogene Co (SHSE:688315) Overvalued in 2026?
Based on GuruFocus' analysis, Novogene Co stock appears to be undervalued.
The current stock price of ¥11.94 is trading 25.3% below its estimated GF Value™ of ¥15.99.
GuruFocus considers Novogene Co to be Modestly Undervalued.
Key valuation signals for SHSE:688315:
Interest Coverage: 76.70 (16% below median its 10-year median of 90.95)
GF Value™: ¥15.99 vs. price of ¥11.94 (25.3% below fair value)
Industry Position: 27.7% below the Biotechnology median (#191 of 376)
No single metric tells the full story. See the SHSE:688315 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novogene Co Ltd is engaged in providing multi-level scientific research and technical services and solutions for life science basic research, medical and clinical application research, and independent development and innovation of genetic testing medical equipment.
84GF Score
Get the complete analysis for SHSE:688315
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688315 has been successfully added to your 
